Bioinvent Enters Into Collaboration With Pfizer To Select Second Target For Cancer Immunotherapy Research

News provided by

News Updates on Industries

Dec 26, 2019, 13:10 EST

Dec 26, 2019, 13:10 /Comserve / -- The company announced that the second target has been selected by Pfizer under their research partnership and license agreement which has been further extended by six months

Image placeholder

BioInvent International AB (OMXS: BINV) announced that it is increasing the term for cancer immunotherapy research with Pfizer Inc. (NYSE: PFE) along with their license agreement by six months as the latter has selected the second target for the research. The agreement between BioInvent and Pfizer was for the development of antibodies that target tumor-associated myeloid cells. BioInvent’s registered F.I.R.S.TTM drug delivery platform is used for discovering these myeloid cells. Both the companies entered into this agreement in December 2016 and have been working together since then for the identification and characterization of targets and various other antibodies that bind to those targets.

According to a statement by the CEO of BioInvent, Martin Welschof, the company’s high quality n-CoDeR® library for antibodies helps in the identification of targets, providing a patient-centric approach that leads to the discovery of new human bodies and interesting targets. The extension of this agreement by six months would provide the companies with extra time to select more targets along with their corresponding antibodies.

About BioInvent International AB

BioInvent International AB is a company at clinical stage that works in the research and development of novel immuno-modulatory antibodies for the treatment of cancer. Presently, BioInvent is involved in two clinical trials, one is in Phase I for the treatment of hematological cancer and the other is in Phase II for the treatment of solid tumors. The company is mainly involved in research collaborations with leading pharmaceutical companies with license agreements for the development and commercialization of antibodies. Further, BioInvent produces antibodies for various third parties in its manufacturing unit which is another source of revenue for the company.

Independent Writer

For more information, please contact:

Jackie Hurtado

News Updates on Industries
Tel: +1-612-695-8655

Related Links

Also from this source

Fiat Chrysler Automobiles And Peugeot S.A. All Set To Merge

The groups FCA and PSA to combine to give rise to sustainable mobility through leadership, resources

Hg to acquire major shareholding in Intelerad Medical Systems from Novacap

The announcement to acquire a large stake in Intelerad Medical Systems had been made by the UK based